Literature DB >> 8834908

Comparison of fluconazole and amphotericin B in prophylaxis of experimental Candida endocarditis caused by non-C. albicans strains.

A S Bayer1, M D Witt, E Kim, M A Ghannoum.   

Abstract

Amphotericin B (1 mg/kg of body weight, intravenous) and fluconazole (100 mg/kg, intraperitoneal) were compared in the prophylaxis of experimental Candida endocarditis caused by drug-susceptible, non-C. albicans strains C. tropicalis and C. parapsilosis. Neither antifungal agent was effective at preventing endocarditis due to either Candida strain when either agent was administered in a single-dose regimen (1 h prior to fungal challenge); the prophylactic efficacy of both agents increased substantially when a second prophylactic dose was given (24 h postchallenge). The excellent prophylactic efficacy of fluconazole, a fungistatic agent, underscores the importance of microbistatic mechanisms in endocarditis prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834908      PMCID: PMC163144     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci.

Authors:  U Fluckiger; P Francioli; J Blaser; M P Glauser; P Moreillon
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

Review 2.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

3.  Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. albicans strains.

Authors:  M D Witt; T Imhoff; C Li; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

4.  Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

Authors:  D J Winston; P H Chandrasekar; H M Lazarus; J L Goodman; J L Silber; H Horowitz; R K Shadduck; C S Rosenfeld; W G Ho; M Z Islam; D N Buell
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

5.  Pharmacokinetics and bioavailability of fluconazole in patients with AIDS.

Authors:  D DeMuria; A Forrest; J Rich; J M Scavone; L G Cohen; P H Kazanjian
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

6.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

7.  A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

Authors:  W G Powderly; D Finkelstein; J Feinberg; P Frame; W He; C van der Horst; S L Koletar; M E Eyster; J Carey; H Waskin
Journal:  N Engl J Med       Date:  1995-03-16       Impact factor: 91.245

8.  Nosocomial acquisition of Candida parapsilosis: an epidemiologic study.

Authors:  V Sanchez; J A Vazquez; D Barth-Jones; L Dembry; J D Sobel; M J Zervos
Journal:  Am J Med       Date:  1993-06       Impact factor: 4.965

9.  Candida tropicalis: a major pathogen in immunocompromised patients.

Authors:  J R Wingard; W G Merz; R Saral
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

10.  Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis.

Authors:  M D Witt; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.